| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 243K | 17.2M | 44.76M | 52.3M |
| Revenue Growth % | - | 69.78% | 1.6% | 0.17% |
| Cost of Goods Sold | 387K | 1.73M | 94.4M | 0 |
| COGS % of Revenue | 1.59% | 0.1% | 2.11% | - |
| Gross Profit | -144K | 15.47M | -49.65M | 52.3M |
| Gross Margin % | -0.59% | 0.9% | -1.11% | 1% |
| Gross Profit Growth % | - | 108.41% | -4.21% | 2.05% |
| Operating Expenses | 23.8M | 60.11M | 28.84M | 141.2M |
| OpEx % of Revenue | 97.95% | 3.49% | 0.64% | 2.7% |
| Selling, General & Admin | 9.71M | 18.7M | 28.84M | 32.02M |
| SG&A % of Revenue | 39.97% | 1.09% | 0.64% | 0.61% |
| Research & Development | 14.48M | 43.14M | 94.4M | 109.18M |
| R&D % of Revenue | 59.58% | 2.51% | 2.11% | 2.09% |
| Other Operating Expenses | -387K | -1.73M | -94.4M | 0 |
| Operating Income | -23.95M | -44.64M | -78.49M | -88.9M |
| Operating Margin % | -98.55% | -2.6% | -1.75% | -1.7% |
| Operating Income Growth % | - | -0.86% | -0.76% | -0.13% |
| EBITDA | -23.56M | -42.91M | -74.28M | -83.49M |
| EBITDA Margin % | -96.95% | -2.49% | -1.66% | -1.6% |
| EBITDA Growth % | - | -0.82% | -0.73% | -0.12% |
| D&A (Non-Cash Add-back) | 387K | 1.73M | 4.21M | 5.41M |
| EBIT | -21.14M | -40.93M | -78.49M | -88.9M |
| Net Interest Income | -259K | 3.32M | 15.47M | 14.72M |
| Interest Income | 43K | 3.42M | 15.47M | 14.72M |
| Interest Expense | 302K | 98K | 0 | 0 |
| Other Income/Expense | 2.5M | 3.62M | 18.26M | 5.33M |
| Pretax Income | -21.44M | -41.02M | -60.23M | -83.57M |
| Pretax Margin % | -88.24% | -2.39% | -1.35% | -1.6% |
| Income Tax | 0 | 2.57M | 8.03M | -5.51M |
| Effective Tax Rate % | 1% | 1.06% | 1.13% | 0.93% |
| Net Income | -21.44M | -43.59M | -68.25M | -78.06M |
| Net Margin % | -88.24% | -2.53% | -1.53% | -1.49% |
| Net Income Growth % | - | -1.03% | -0.57% | -0.14% |
| Net Income (Continuing) | -21.44M | -43.59M | -68.25M | -78.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.62 | -1.16 | -1.82 | -2.09 |
| EPS Growth % | - | 0.68% | -0.57% | -0.15% |
| EPS (Basic) | -3.62 | -1.16 | -1.82 | -2.09 |
| Diluted Shares Outstanding | 5.93M | 37.47M | 37.47M | 37.42M |
| Basic Shares Outstanding | 5.93M | 37.47M | 37.47M | 37.42M |
| Dividend Payout Ratio | - | - | - | - |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Current Assets | 108.92M | 366.9M | 278.27M | 257.96M |
| Cash & Short-Term Investments | 108.15M | 362.13M | 271.18M | 248.31M |
| Cash Only | 39.3M | 184.44M | 140.6M | 27.39M |
| Short-Term Investments | 68.86M | 177.69M | 130.58M | 220.92M |
| Accounts Receivable | 490K | 1.27M | 2.45M | 1.26M |
| Days Sales Outstanding | 736.01 | 27.04 | 19.99 | 8.77 |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 272K | 2.81M | 4.64M | 8.4M |
| Total Non-Current Assets | 33.08M | 47.59M | 86.57M | 66.64M |
| Property, Plant & Equipment | 22.14M | 33.26M | 65.15M | 57.66M |
| Fixed Asset Turnover | 0.01x | 0.52x | 0.69x | 0.91x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 6.42M | 7.81M | 15.92M | 3.45M |
| Other Non-Current Assets | 4.52M | 6.52M | 5.49M | 5.54M |
| Total Assets | 141.99M | 414.49M | 364.84M | 324.6M |
| Asset Turnover | 0.00x | 0.04x | 0.12x | 0.16x |
| Asset Growth % | - | 1.92% | -0.12% | -0.11% |
| Total Current Liabilities | 25.17M | 48.54M | 68.86M | 37.31M |
| Accounts Payable | 1.35M | 2.01M | 1.79M | 533K |
| Days Payables Outstanding | 1.28K | 423.55 | 6.92 | - |
| Short-Term Debt | 0 | 0 | 3.43M | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 5.8M | 5.56M | 4.21M | 5.35M |
| Current Ratio | 4.33x | 7.56x | 4.04x | 6.91x |
| Quick Ratio | 4.33x | 7.56x | 4.04x | 6.91x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 149.36M | 440.38M | 80.81M | 52.43M |
| Long-Term Debt | 30.28M | 0 | 0 | 0 |
| Capital Lease Obligations | 17.96M | 17.06M | 44.8M | 40.19M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 77.41M | 347.14M | 5.08M | 2.01M |
| Total Liabilities | 174.54M | 488.91M | 149.67M | 89.74M |
| Total Debt | 48.93M | 18.57M | 48.23M | 45.78M |
| Net Debt | 9.63M | -165.87M | -92.37M | 18.39M |
| Debt / Equity | - | - | 0.22x | 0.19x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | -79.29x | -455.51x | - | - |
| Total Equity | -32.54M | -74.43M | 215.17M | 234.86M |
| Equity Growth % | - | -1.29% | 3.89% | 0.09% |
| Book Value per Share | -5.49 | -1.99 | 5.74 | 6.28 |
| Total Shareholders' Equity | -32.54M | -74.43M | 215.17M | 234.86M |
| Common Stock | 573K | 2.54M | 26K | 4K |
| Retained Earnings | -33.1M | -76.69M | -144.94M | -223M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | -21K | -274K | 9.33M | 709K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | 24.26M | 29.72M | -91.41M | -109.07M |
| Operating CF Margin % | 99.82% | 1.73% | -2.04% | -2.09% |
| Operating CF Growth % | - | 0.23% | -4.08% | -0.19% |
| Net Income | -21.44M | -43.59M | -68.25M | -78.06M |
| Depreciation & Amortization | 387K | 1.73M | 4.21M | 5.41M |
| Stock-Based Compensation | 375K | 1.96M | 6.92M | 16.2M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.32M | 135K | -7.85M | 7.04M |
| Working Capital Changes | 46.26M | 69.49M | -26.43M | -59.67M |
| Change in Receivables | 0 | -1.27M | -1.18M | 1.19M |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 695K | 721K | -84K | -1.11M |
| Cash from Investing | -74.32M | -122.2M | 45.73M | -88.16M |
| Capital Expenditures | -2.9M | -13.98M | -9.81M | -3.11M |
| CapEx % of Revenue | 11.95% | 0.81% | 0.22% | 0.06% |
| Acquisitions | - | - | - | - |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 39.92M | 239.59M | 1.01M | 84.01M |
| Debt Issued (Net) | - | - | - | - |
| Equity Issued (Net) | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - |
| Other Financing | 0 | 0 | -3.28M | 0 |
| Net Change in Cash | - | - | - | - |
| Free Cash Flow | 21.35M | 15.75M | -101.22M | -112.19M |
| FCF Margin % | 87.88% | 0.92% | -2.26% | -2.15% |
| FCF Growth % | - | -0.26% | -7.43% | -0.11% |
| FCF per Share | 3.60 | 0.42 | -2.70 | -3.00 |
| FCF Conversion (FCF/Net Income) | -1.13x | -0.68x | 1.34x | 1.40x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 2.25M | 3.5M |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -96.99% | -34.69% |
| Return on Invested Capital (ROIC) | - | - | -47.94% | -35.46% |
| Gross Margin | -59.26% | 89.92% | -110.93% | 100% |
| Net Margin | -8823.87% | -253.45% | -152.5% | -149.26% |
| Debt / Equity | - | - | 0.22x | 0.19x |
| Interest Coverage | -79.29x | -455.51x | - | - |
| FCF Conversion | -1.13x | -0.68x | 1.34x | 1.40x |
| Revenue Growth | - | 6978.19% | 160.21% | 16.84% |
Metagenomi, Inc. Common Stock (MGX) reported $30.9M in revenue for fiscal year 2024. This represents a 12621% increase from $0.2M in 2021.
Metagenomi, Inc. Common Stock (MGX) grew revenue by 16.8% over the past year. This is strong growth.
Metagenomi, Inc. Common Stock (MGX) reported a net loss of $88.7M for fiscal year 2024.
Metagenomi, Inc. Common Stock (MGX) has a return on equity (ROE) of -34.7%. Negative ROE indicates the company is unprofitable.
Metagenomi, Inc. Common Stock (MGX) had negative free cash flow of $92.4M in fiscal year 2024, likely due to heavy capital investments.